<DOC>
	<DOCNO>NCT01856933</DOCNO>
	<brief_summary>The purpose study evaluate effectiveness Prostate Specific Membrane Antigen ( PSMA ADC ) , well safety side effect patient advance brain tumor . This study also study body metabolizes ( break ) PSMA ADC .</brief_summary>
	<brief_title>BrUOG 263 : Prostate Specific Membrane Antigen ( PSMA ) Glioblastoma Multiforme ( GBM )</brief_title>
	<detailed_description>PSMA expression demonstrate tumor neovasculature Glioblastoma Multiforme ( GBM ) immunohistochemical staining . Strong reactivity antibody component PSMA ADC observe endothelial cell new tumor blood vessel GBM . Since endothelial cell locate luminal surface blood vessel , PSMA ADC need cross blood brain barrier reach target . Following bind internalization PSMA ADC , cytotoxic component PSMA ADC release destroy neovasculature support tumor growth . Therefore , PSMA ADC may active treatment GBM . Bevacizumab , inhibitor angiogenesis , show effective improve progression-free survival single agent . Thus PSMA ADC , target tumor angiogenesis mechanism different bevacizumab , may novel therapeutic modality GBM . A phase 2 study PSMA ADC propose patient GBM progress standard treatment include radiation , temozolomide bevacizumab . A phase 1 study PSMA ADC prostate cancer ongoing phase 2 dose level 2.5 mg/kg IV every 3 week define . Treatment bevacizumab failure patient GBM major unmet medical need . If activity demonstrate trial , definitive randomize study would propose .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Gliosarcoma</mesh_term>
	<criteria>Males female Histologically confirm GBM ( Patients gliosarcoma also eligible ) Assessable measurable disease MRI Progression prior treatment include radiation , temozolomide bevacizumab . &gt; 4 week since prior chemotherapy , bevacizumab systemic treatment &gt; 3 week prior radiation . age &gt; 18 year Weight &lt; 150 kg . Karnofsky performance score &gt; 60 Life expectancy &gt; 12 week Brain MRI within 21 day prior registration Laboratory result requirement Absolute neutrophil count ( ANC ) ≥ 1000/mm3 . Platelets ( Plt ) ≥ 100,000/mm3 Hemoglobin ( Hgb ) ≥ 8.0 g/dL Total bilirubin ≤ 2.0 mg/dL Serum alanine transferase/ Serum aspartate transaminase ( ALT/AST ) ≤ 2.5x upper limit normal ( ULN ) Serum creatinine ≤ 2.0 mg/dL Pancreatic Amylase ( pamylase ) ≤ ULN Negative serum pregnancy test woman childbearing potential Stable corticosteroid dose least 14 day prior registration Women childbearing potential must negative pregnancy test . Men woman childbearing potential must willing consent use effective contraception treatment least 3 month thereafter . Patients must enzymeinducing antiepileptic drug ( EIAED ) . Patients may nonenzyme induce antiepileptic drug ( NEIAED ) may take antiepileptic drug . A list AED cause modest induction hepatic metabolic enzyme discuss NonGBM primary invasive malignant neoplasm within five year prior screen except : keratinocyte ( nonmelanoma ) ( i.e. , basal cell , squamous cell ) carcinoma skin ; lowgrade papillary superficial transitional cell carcinoma bladder.However , patient stage 1 cancer require cancer therapy include chemotherapy hormone therapy , lifespan great 3 year without treatment expect ( early stage prostate cancer ) may enrol . Clinically significant cardiac disease ( New York Heart Association Class III/ IV severe debilitate pulmonary disease Subjects QTc &gt; 500 msec ( either Bazzett 's Fridericia 's method ) Radiation therapy , cytotoxic chemotherapy , bevacizumab treatment GBM within previous three week Evidence active infection require ongoing intravenous antibiotic therapy Any toxicity ≥ grade 2 ( nonlaboratory ) ( NCI CTCAE , Version 4.03 ) prior first dose study drug Prior treatment PSMA ADC therapy target PSMA , antibody drug conjugate ( ADC ) product contain monomethyl auristatin E ( MMAE ) ( e.g. , brentuximab vedotin , glembatumumab vedotin , ASG5ME ) Known hypersensitivity reaction PSMA ADC component . Any medical condition opinion Investigator may interfere subject 's participation compliance study Patients prior history pancreatitis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>GBM</keyword>
	<keyword>Glioblastoma Multiforme</keyword>
	<keyword>Gliosarcoma</keyword>
</DOC>